The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
What does the current treatment landscape look like in psoriasis and PsA?
Ulrich Mrowietz
Laura Coates
Alice Gottlieb
Paolo Gisondi
André CarvalhoDuring the Psoriasis Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA.
What does the current treatment landscape look like in psoriasis and PsA?
The recorded discussion was chaired by André Carvalho and featured Alice Gottlieb, Laura Coates, Paolo Gisondi, and Ulrich Mrowietz. The steering committee discussed how treatment landscapes differ between countries, including how access and cost affect treatment availability. The experts also spoke about the role of comorbidities in treatment selection. Finally, the role of Janus kinase inhibitors in psoriasis was discussed.